

Errata to the FDA Briefing Document
Arthritis Advisory Committee Meeting
August 3, 2017

1. On page 40, first paragraph, the current text:

Using 25-75% of the upper confidence interval bound leads to NI margins in the range of approximately 0.125 to 0.375 utilizing historical data across TNF inhibitors, or approximately 0.06 to 0.17 utilizing only historical data for adalimumab.

Should be revised to read (change bolded and underlined):

Using 25-75% of the upper confidence interval bound leads to NI margins in the range of approximately 0.125 to 0.375 utilizing historical data across TNF inhibitors, or approximately **0.10 to 0.30** utilizing only historical data for adalimumab.

2. On page 51, Table 23, row 1, column 1, the text should read:

A3921092 rather than A39210912